Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the ORR associated with Doxil in combination with
carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
Phase:
Phase 2
Details
Lead Sponsor:
US Oncology Research
Collaborators:
Ortho Biotech, Inc. Tibotec Pharmaceutical Limited